The Efficacy and Safety of Protoxin in Subjects With Moderate to Severe Glabellar Lines

Exclusion criteria

• ✕. A person who has or is accompanied by the following diseases at the time of screening
• ✕. A person with systemic neuromuscular junction disorder that can affect neuromuscular function \[myasthenia gravis (MG), Lambert-Eaton myasthenic syndrome, amyotrophic lateral sclerosis (ALS), etc.\]
• ✕. A person with a history of facial paralysis or ptosis
• ✕. A person who has skin abnormalities such as infections, skin diseases, scars, etc. at the site to be administered
• ✕. A person who has wrinkles to the extent that the glabellar lines cannot be physically flattened, such as when wrinkles are not straightened by hand
• ✕. A person who is taking the following drugs
• ✕. Within 4 weeks of screening: Drugs with muscle relaxation action, such as muscle relaxants, spectinomycin hydrochloride, aminoglycoside antibiotics, polypeptide antibiotics, tetracycline antibiotics, lincomycin antibiotics, anticholinergics, benzodiazepines and similar drugs, and benzamide drugs \[However, for muscle relaxants, benzodiazepines and similar drugs, a person who has stably maintained administration of them from within 4 weeks from the time of screening (the same drug is maintained without changing the usage and dose), and is not expected to change in ingredients, usage, and dose of them during the clinical trial period can be enrolled\]
• ✕. A person who has administered aspirin or NSAIDs within 7 days before administration of the investigational product (However, low-dose aspirin (100 mg/day or less) administered for antithrombotic purposes is permitted)